{"database":"ENA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"center_name":["Medical Sciences, Uppsala University"],"full_dataset_link":["https://www.ebi.ac.uk/ena/browser/view/PRJNA854630"],"scientific_name":["Homo sapiens"],"long_description":["We developed a phenotypic screening platform that identified statins as enhancers of immune cell-induced cancer cell death. Statins are currently gaining interest as repurposing candidates for use in oncology as increasing evidence supports that statins exert anti-cancer effects. Considering also our findings, the clinical benefits described for cancer patients receiving statins might be due to a combined effect on both cancer- and immune cells. Studying gene expression profiles is a well established approach for investigating a compound's mode of action. We performed transcriptome-wide gene expression profiling on the human colorectal cancer cell line HCT116-GFP and peripheral blood mononuclear cells (PBMCs). Monocultured and co-cultured cells were treated with DMSO vehicle or pitavastatin (1µM or 10µM) for 24 hours before gene expression was analyzed using a Human Clariom S array. Overall design: The colorectal cancer cell line HCT116-GFP and PBMCs were cultured as monocultures or co-cultured. Monocultures and co-cultures were treated with DMSO vehicle or pitavastatin (1µM or 10µM) for 24h. Differentially expressed genes in pitavastatin-treated cells compared to DMSO were then analysed in the different cultures."],"tag":["xref:PubMed:36803614"],"repository":["ENA"],"additional_accession":[]},"is_claimable":false,"name":"Expression profiling of pitavastatin in a tumor-immune model in vitro","description":"Expression profiling of pitavastatin in a tumor-immune model in vitro","dates":{"last_updated":"2025-09-24","first_public":"2023-02-20"},"accession":"PRJNA854630","cross_references":{"GEO":["GSE207280"],"taxon":["9606"],"PubMed":["36803614"]}}